Dr. Herbst on the Next Generation of Lung Cancer Trials

Roy S. Herbst, MD, PhD
Published: Wednesday, Oct 01, 2014

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses next generation lung cancer trials.

The next generation of lung cancer trials will try to match new biomarkers with new therapeutic agents.

The BATTLE trials, which began in 2005, had all patients freshly biopsied and randomized to 1 of 4 arms of therapy. Researchers began BATTLE-1 with hypotheses regarding biomarkers and outcomes and analyzed data in real time. This trial identified relationships between markers and drugs, including the correlation between VEGFR2 and activity of angiogenesis inhibitors.

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses next generation lung cancer trials.

The next generation of lung cancer trials will try to match new biomarkers with new therapeutic agents.

The BATTLE trials, which began in 2005, had all patients freshly biopsied and randomized to 1 of 4 arms of therapy. Researchers began BATTLE-1 with hypotheses regarding biomarkers and outcomes and analyzed data in real time. This trial identified relationships between markers and drugs, including the correlation between VEGFR2 and activity of angiogenesis inhibitors.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x